Skip to main content

Closed

LTRN: Lantern Pharma Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin0.0%

ROIC-473.9%

Financially safe

Stretched

Debt / equity0.02×

Interest coverage0.0×

Current ratio1.87×

Lantern Pharma Inc.

LTRNNASDAQ Capital Market·USD·Closed

Lantern Pharma Inc.

LTRNNASDAQ·USD·Closed

$2.63

−0.75%

$2.63

−$0.02 (0.75%)

52W Range

33thpctl

Volume

0.22×avg

Mkt Cap

33.56MUSD

P/E

-1.8TTM

Div Yield

–ann

52W Range

33thpctl

Volume

0.22×avg

Market Cap

33.56MUSD

P/E Ratio

-1.8TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings